{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:15:26Z","timestamp":1769825726293,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21273254"],"award-info":[{"award-number":["21273254"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21703290"],"award-info":[{"award-number":["21703290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21773015"],"award-info":[{"award-number":["21773015"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["817001"],"award-info":[{"award-number":["817001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["2202021"],"award-info":[{"award-number":["2202021"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.clml.2021.11.007","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:58:34Z","timestamp":1636977514000},"page":"e350-e362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["State-of-the-Art Review on Myelofibrosis Therapies"],"prefix":"10.1016","volume":"22","author":[{"given":"Fuping","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0420-3564","authenticated-orcid":false,"given":"Qiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.11.007_bib0001","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1007\/s12325-020-01314-0","article-title":"The myeloproliferative neoplasm landscape: a patient's eye view","volume":"37","author":"Petruk","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2021.11.007_bib0002","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.11.007_bib0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.007_bib0004","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/cancers13040800","article-title":"Janus kinases in leukemia","volume":"13","author":"Raivola","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2021.11.007_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2020.1749606","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"61","author":"Bose","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.11.007_bib0006","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","article-title":"Fedratinib in myelofibrosis","volume":"4","author":"Mullally","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.11.007_bib0007","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.007_bib0008","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.11.007_bib0009","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ejh.13579","article-title":"Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression","volume":"106","author":"Bartels","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2021.11.007_bib0010","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque Paz","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.11.007_bib0011","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/hematology.2020000130","article-title":"Genomics of myelodysplastic syndrome\/myeloproliferative neoplasm overlap syndromes","volume":"2020","author":"Patnaik","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.11.007_bib0012","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.11.007_bib0013","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.11.007_bib0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.11.007_bib0015","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.11.007_bib0016","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2021.11.007_bib0017","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.11.007_bib0018","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of Momelotinib versus ruxolitinib in janus kinase inhibitor\u2013na\u00a8\u0131ve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.11.007_bib0019","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.11.007_bib0020","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.11.007_bib0021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood.V128.22.LBA-5.LBA-5","article-title":"Results of the persist-2 phase 3 study of Pacritinib (PAC) versus Best Available Therapy (BAT), including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and platelet counts <100,000\/\u00b5l","volume":"128","author":"Mascarenhas","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.007_bib0022","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.leukres.2018.06.014","article-title":"Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms","volume":"71","author":"Berdeja","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.11.007_bib0023","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/leu.2016.215","article-title":"A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis","volume":"31","author":"Verstovsek","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.11.007_bib0024","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.11.007_bib0025","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2021.11.007_bib0026","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-18-4089","article-title":"Activation of JAK\/STAT signaling in megakaryocytes sustains myeloproliferation in vivo","volume":"25","author":"Woods","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.11.007_bib0027","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cell.2012.06.032","article-title":"Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL","volume":"150","author":"Wen","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.clml.2021.11.007_bib0028","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-19-1005","article-title":"Aurora kinase a inhibition provides clinical benefit, normalizes megakaryocytes, and reduces bone marrow fibrosis in patients with myelofibrosis: a phase I trial","volume":"25","author":"Gangat","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.11.007_bib0029","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of the telomerase inhibitor imetelstat for myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.11.007_bib0030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/01.HS9.0000564088.98639.88","article-title":"Favorable overall survival with Imetelstat treatment correlates with other clinical benefits in intermediate 2 or high risk myelofibrosis relapsed refractory to janus kinase inhibitor","volume":"3","author":"Kuykendall","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2021.11.007_bib0031","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-018-0166-4","article-title":"High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals","volume":"9","author":"Holmstrom","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.11.007_bib0032","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2018-99-115362","article-title":"PRM-151 in myelofibrosis: efficacy and safety in an open label extension study","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.11.007_bib0033","first-page":"582","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of oncology: official journal of the European Society for","volume":"30","author":"Hamid","year":"2019","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2021.11.007_bib0034","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/bloodadvances.2020003829","article-title":"Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis","volume":"5","author":"Pemmaraju","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.11.007_bib0035","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2020.1830056","article-title":"Pembrolizumab for the treatment of Hodgkin lymphoma","volume":"20","author":"Al Hadidi","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clml.2021.11.007_bib0036","first-page":"12","article-title":"Phase II study of single-agent nivolumab in patients with myelofibrosis","volume":"9","author":"Abou Dalle","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2021.11.007_bib0037","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41408-018-0166-4","article-title":"High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals","volume":"9","author":"Holmstrom","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.11.007_bib0038","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/21678707.2019.1664900","article-title":"Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis","volume":"7","author":"Bose","year":"2019","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.clml.2021.11.007_bib0039","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.exphem.2016.08.007","article-title":"Preclinical rationale for TGF-beta inhibition as a therapeutic target for the treatment of myelofibrosis","volume":"44","author":"Ceglia","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2021.11.007_bib0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3324\/haematol.2018.198887","article-title":"Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase II, open-label, dose-finding study","volume":"104","author":"Cappellini","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.11.007_bib0041","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41375-019-0638-y","article-title":"Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations","volume":"34","author":"Austin","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.11.007_bib0042","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3324\/haematol.2017.181297","article-title":"Benefits and pitfalls of pegylated interferon-alpha2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study","volume":"103","author":"Ianotto","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.11.007_bib0043","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"Sorensen","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.11.007_bib0044","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.leukres.2017.06.005","article-title":"Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis","volume":"60","author":"Gowin","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.11.007_bib0045","first-page":"1058","article-title":"Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.11.007_bib0046","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/leu.2016.299","article-title":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis","volume":"31","author":"Schlenk","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.11.007_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106272","article-title":"A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post\u2013polycythemia vera\/essential thrombocythemia myelofibrosis (post\u2013PV\/ET MF)","volume":"88","author":"Mascarenhas","year":"2020","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2021.11.007_bib0048","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/10428194.2018.1543876","article-title":"A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis","volume":"60","author":"Bose","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.11.007_bib0049","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/bloodadvances.2019001212","article-title":"Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b\/2 dose-finding study","volume":"4","author":"Gupta","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.11.007_bib0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13045-018-0661-x","article-title":"A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis","volume":"11","author":"Couban","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2021.11.007_bib0051","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.3324\/haematol.2018.209965","article-title":"Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis","volume":"104","author":"Durrant","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.11.007_bib0052","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.11.007_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191264","article-title":"17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model","volume":"13","author":"Joshi","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2021.11.007_bib0054","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41594-019-0309-8","article-title":"Bromodomain biology and drug discovery","volume":"26","author":"Zaware","year":"2019","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.clml.2021.11.007_bib0055","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/1078-0432.CCR-11-1541","article-title":"Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells","volume":"17","author":"Fiskus","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2021.11.007_bib0056","doi-asserted-by":"crossref","first-page":"18925","DOI":"10.1038\/s41598-019-55176-w","article-title":"Glycogen synthase kinase-3beta inhibition with 9-ING-41 attenuates the progression of pulmonary fibrosis","volume":"9","author":"Jeffers","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2021.11.007_bib0057","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1038\/s41375-019-0379-y","article-title":"Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling","volume":"33","author":"Fisher","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.11.007_bib0058","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3324\/haematol.2018.206151","article-title":"State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019","volume":"104","author":"McLornan","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.11.007_bib0059","doi-asserted-by":"crossref","first-page":"100716","DOI":"10.1016\/j.blre.2020.100716","article-title":"Management of challenging myelofibrosis after JAK inhibitor failure and\/or progression","volume":"42","author":"Scherber","year":"2020","journal-title":"Blood Rev"},{"key":"10.1016\/j.clml.2021.11.007_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101254","article-title":"What are the molecular mechanisms driving the switch from MPNs to leukemia?","volume":"34","author":"Wang","year":"2021","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021024393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:53Z","timestamp":1761871133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021024393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2152265021024393"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.11.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State-of-the-Art Review on Myelofibrosis Therapies","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}